Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics Among Healthcare Movers

Seeking AlphaApr 22 22:01

Lexicon Pharmaceuticals to Host 2024 Investor Day

Business and scientific updates will be presented by Lonnel Coats, Lexicon's chief executive officer; Jeff Wade, Lexicon's president and chief financial officer.

Globe NewswireApr 18 20:00

Needham: Reiterates that Lexicon Pharmaceuticals (LXRX.US) holds the rating.

Needham: Reiterates that Lexicon Pharmaceuticals (LXRX.US) holds the rating.

Zhitong FinanceApr 11 18:20

Needham Reiterates Hold on Lexicon Pharmaceuticals

Needham analyst Joseph Stringer reiterates Lexicon Pharmaceuticals with a Hold.

Analyst UpgradesApr 11 18:20

Lexicon Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/11/2024 — Needham Reiterates → Hold 05/31/2023 296.04% Citigroup $6 → $8 Maintains Buy 05/30/2023 — Ne

BenzingaApr 11 18:19

Lexicon Tech Solutions Welcomes New VP of Channel Development

CONYERS, Ga., April 3, 2024 /PRNewswire/ -- Lexicon Tech Solutions, a leading provider of innovative technology solutions, is pleased to announce the appointment of Jenny Taylor as the new Vice Presi

PR NewswireApr 3 21:15